Climb Bio
CLYM
22 hedge funds and large institutions have $47.8M invested in Climb Bio in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 9 closing their positions.
5% more capital invested
Capital invested by funds: $45.7M → $47.8M (+$2.13M)
1.21% less ownership
Funds ownership: 56.94% → 55.73% (-1.2%)
24% less funds holding
Funds holding: 29 → 22 (-7)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.11M |
| 2 |
AI
Atom Investors
Austin,
Texas
|
+$130K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$111K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$10.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$992K |
| 2 |
Goldman Sachs
New York
|
-$492K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$468K |
| 4 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$203K |
| 5 |
E
Ergoteles
New York
|
-$80K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | -$10 | -3 | -7% |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$265 | +83 | +296% |
|
CLYM Hedge Fund Activity: Q3 2022 in Review
22 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q3 2022, worth a combined $47.8M — up 4.7% from $45.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CLYM and 2 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $1.11M. The largest seller was Silverarc Capital Management, cutting an estimated $992K.
- 22 institutional investors held Climb Bio (CLYM) as of Q3 2022, down from 29 in Q2 2022.
- Funds reported $47.8M of Climb Bio stock for Q3 2022, up 4.7% quarter-over-quarter.
- 2 funds opened new Climb Bio positions in Q3 2022 and 9 closed out, a net change of -7 holders.
- The largest Climb Bio buyer in Q3 2022 was Driehaus Capital Management, an estimated $1.11M added.
- The largest Climb Bio seller in Q3 2022 was Silverarc Capital Management, an estimated $992K sold.
Based on aggregated 13F filings for Q3 2022.